MedTrace Logo

Epcoritamab in Previously Treated WM

NCT06510491 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-13

No results posted yet for this study

Summary

This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM).

The names of the study drug involved in this study is:

-Epcoritamab (a type of antibody)

Conditions

Interventions

DRUG

Epcoritamab

Bispecific antibody, via subcutaneous (under the skin) injection per protocol.

Sponsors & Collaborators

  • Genmab

    collaborator INDUSTRY

  • Gottfried von Keudell, MD PhD

    lead OTHER

Principal Investigators

  • Gottfried von Keudell, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-06
Primary Completion
2027-04-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06510491 on ClinicalTrials.gov